AAPL287.68+5.94 (+2.11%) ▲|ABBV251.31-3.00 (-1.18%) ▼|ABT90.94-1.77 (-1.91%) ▼|ACN124.80+0.06 (+0.05%) ▲|ADBE204.94-1.50 (-0.72%) ▼|AMAT737.76+43.12 (+6.21%) ▲|AMD582.51+43.02 (+7.97%) ▲|AMGN362.38+1.83 (+0.51%) ▲|AMT164.73-3.94 (-2.34%) ▼|AMZN237.74-2.40 (-1.00%) ▼|AVGO378.85+6.40 (+1.72%) ▲|AXP339.50-1.39 (-0.41%) ▼|BA215.84+1.15 (+0.54%) ▲|BAC57.06-0.83 (-1.43%) ▼|BKNG178.20-4.21 (-2.31%) ▼|BLK960.00+9.83 (+1.03%) ▲|BMY57.87-0.69 (-1.18%) ▼|BNY144.79+0.99 (+0.69%) ▲|BRK-B499.25+3.25 (+0.66%) ▲|C139.80-2.69 (-1.89%) ▼|CAT1,065.48+32.29 (+3.13%) ▲|CL91.57-0.83 (-0.90%) ▼|CMCSA24.46+0.24 (+0.97%) ▲|COF201.29-0.99 (-0.49%) ▼|COP103.99-0.21 (-0.20%) ▼|COST934.68-12.00 (-1.27%) ▼|CRM157.26-0.67 (-0.42%) ▼|CSCO117.52-0.18 (-0.15%) ▼|CVS103.91+0.33 (+0.32%) ▲|CVX166.05-2.43 (-1.44%) ▼|DE633.53+8.52 (+1.36%) ▲|DHR191.06-1.72 (-0.89%) ▼|DIS96.48-1.40 (-1.43%) ▼|DUK127.37-0.97 (-0.75%) ▼|EMR143.27+0.45 (+0.32%) ▲|FDX312.12-13.28 (-4.08%) ▼|GD354.24+6.17 (+1.77%) ▲|GE372.51-1.21 (-0.32%) ▼|GEV1,172.02+69.51 (+6.30%) ▲|GILD126.34+0.01 (+0.01%) ▲|GM77.10-0.24 (-0.31%) ▼|GOOG353.94+2.66 (+0.76%) ▲|GOOGL357.21+3.56 (+1.01%) ▲|GS1,012.89-7.32 (-0.72%) ▼|HD353.01+2.20 (+0.63%) ▲|HON221.55-6.25 (-2.74%) ▼|IBM282.10+4.10 (+1.47%) ▲|INTC140.61+8.89 (+6.75%) ▲|INTU261.52-4.88 (-1.83%) ▼|ISRG399.51-6.46 (-1.59%) ▼|JNJ254.93-3.59 (-1.39%) ▼|JPM327.10-2.29 (-0.70%) ▼|KO81.13-1.52 (-1.84%) ▼|LIN518.90+7.84 (+1.53%) ▲|LLY1,206.97-22.96 (-1.87%) ▼|LMT509.05+6.98 (+1.39%) ▲|LOW220.66+1.01 (+0.46%) ▲|LRCX436.60+25.69 (+6.25%) ▲|MA513.44+3.80 (+0.75%) ▲|MCD270.33+3.15 (+1.18%) ▲|MDLZ57.83-2.32 (-3.86%) ▼|MDT78.50-2.44 (-3.01%) ▼|META560.70-1.91 (-0.34%) ▼|MMM162.02-0.42 (-0.26%) ▼|MO72.03-2.02 (-2.73%) ▼|MRK128.44-0.95 (-0.73%) ▼|MS209.35-2.37 (-1.12%) ▼|MSFT371.19+2.62 (+0.71%) ▲|MU1,162.07+16.79 (+1.47%) ▲|NEE88.09-0.57 (-0.64%) ▼|NFLX71.87-1.91 (-2.59%) ▼|NKE41.17-0.31 (-0.76%) ▼|NOW99.31-0.66 (-0.66%) ▼|NVDA198.69+3.72 (+1.91%) ▲|ORCL147.31-0.45 (-0.30%) ▼|PEP135.20-3.49 (-2.51%) ▼|PFE24.10-0.28 (-1.13%) ▼|PG146.35-2.10 (-1.41%) ▼|PLTR116.58+0.88 (+0.76%) ▲|PM180.71-2.16 (-1.18%) ▼|QCOM184.23-4.49 (-2.38%) ▼|RTX189.60+2.27 (+1.21%) ▲|SBUX102.17-1.90 (-1.82%) ▼|SCHW92.12+1.57 (+1.73%) ▲|SO96.20-0.55 (-0.57%) ▼|SPG224.14-3.43 (-1.51%) ▼|T20.65-1.18 (-5.39%) ▼|TMO503.65-2.77 (-0.55%) ▼|TMUS167.70-6.28 (-3.61%) ▼|TSLA421.79+9.95 (+2.42%) ▲|TXN299.68+14.20 (+4.97%) ▲|UBER72.17-3.34 (-4.42%) ▼|UNH416.17-3.66 (-0.87%) ▼|UNP271.92-0.78 (-0.29%) ▼|UPS107.49-0.52 (-0.48%) ▼|USB60.57-0.20 (-0.32%) ▼|V343.09+1.44 (+0.42%) ▲|VZ42.32-1.79 (-4.05%) ▼|WFC82.79-0.72 (-0.86%) ▼|WMT113.08-1.52 (-1.33%) ▼|XOM136.52+0.46 (+0.33%) ▲|AAPL287.68+5.94 (+2.11%) ▲|ABBV251.31-3.00 (-1.18%) ▼|ABT90.94-1.77 (-1.91%) ▼|ACN124.80+0.06 (+0.05%) ▲|ADBE204.94-1.50 (-0.72%) ▼|AMAT737.76+43.12 (+6.21%) ▲|AMD582.51+43.02 (+7.97%) ▲|AMGN362.38+1.83 (+0.51%) ▲|AMT164.73-3.94 (-2.34%) ▼|AMZN237.74-2.40 (-1.00%) ▼|AVGO378.85+6.40 (+1.72%) ▲|AXP339.50-1.39 (-0.41%) ▼|BA215.84+1.15 (+0.54%) ▲|BAC57.06-0.83 (-1.43%) ▼|BKNG178.20-4.21 (-2.31%) ▼|BLK960.00+9.83 (+1.03%) ▲|BMY57.87-0.69 (-1.18%) ▼|BNY144.79+0.99 (+0.69%) ▲|BRK-B499.25+3.25 (+0.66%) ▲|C139.80-2.69 (-1.89%) ▼|CAT1,065.48+32.29 (+3.13%) ▲|CL91.57-0.83 (-0.90%) ▼|CMCSA24.46+0.24 (+0.97%) ▲|COF201.29-0.99 (-0.49%) ▼|COP103.99-0.21 (-0.20%) ▼|COST934.68-12.00 (-1.27%) ▼|CRM157.26-0.67 (-0.42%) ▼|CSCO117.52-0.18 (-0.15%) ▼|CVS103.91+0.33 (+0.32%) ▲|CVX166.05-2.43 (-1.44%) ▼|DE633.53+8.52 (+1.36%) ▲|DHR191.06-1.72 (-0.89%) ▼|DIS96.48-1.40 (-1.43%) ▼|DUK127.37-0.97 (-0.75%) ▼|EMR143.27+0.45 (+0.32%) ▲|FDX312.12-13.28 (-4.08%) ▼|GD354.24+6.17 (+1.77%) ▲|GE372.51-1.21 (-0.32%) ▼|GEV1,172.02+69.51 (+6.30%) ▲|GILD126.34+0.01 (+0.01%) ▲|GM77.10-0.24 (-0.31%) ▼|GOOG353.94+2.66 (+0.76%) ▲|GOOGL357.21+3.56 (+1.01%) ▲|GS1,012.89-7.32 (-0.72%) ▼|HD353.01+2.20 (+0.63%) ▲|HON221.55-6.25 (-2.74%) ▼|IBM282.10+4.10 (+1.47%) ▲|INTC140.61+8.89 (+6.75%) ▲|INTU261.52-4.88 (-1.83%) ▼|ISRG399.51-6.46 (-1.59%) ▼|JNJ254.93-3.59 (-1.39%) ▼|JPM327.10-2.29 (-0.70%) ▼|KO81.13-1.52 (-1.84%) ▼|LIN518.90+7.84 (+1.53%) ▲|LLY1,206.97-22.96 (-1.87%) ▼|LMT509.05+6.98 (+1.39%) ▲|LOW220.66+1.01 (+0.46%) ▲|LRCX436.60+25.69 (+6.25%) ▲|MA513.44+3.80 (+0.75%) ▲|MCD270.33+3.15 (+1.18%) ▲|MDLZ57.83-2.32 (-3.86%) ▼|MDT78.50-2.44 (-3.01%) ▼|META560.70-1.91 (-0.34%) ▼|MMM162.02-0.42 (-0.26%) ▼|MO72.03-2.02 (-2.73%) ▼|MRK128.44-0.95 (-0.73%) ▼|MS209.35-2.37 (-1.12%) ▼|MSFT371.19+2.62 (+0.71%) ▲|MU1,162.07+16.79 (+1.47%) ▲|NEE88.09-0.57 (-0.64%) ▼|NFLX71.87-1.91 (-2.59%) ▼|NKE41.17-0.31 (-0.76%) ▼|NOW99.31-0.66 (-0.66%) ▼|NVDA198.69+3.72 (+1.91%) ▲|ORCL147.31-0.45 (-0.30%) ▼|PEP135.20-3.49 (-2.51%) ▼|PFE24.10-0.28 (-1.13%) ▼|PG146.35-2.10 (-1.41%) ▼|PLTR116.58+0.88 (+0.76%) ▲|PM180.71-2.16 (-1.18%) ▼|QCOM184.23-4.49 (-2.38%) ▼|RTX189.60+2.27 (+1.21%) ▲|SBUX102.17-1.90 (-1.82%) ▼|SCHW92.12+1.57 (+1.73%) ▲|SO96.20-0.55 (-0.57%) ▼|SPG224.14-3.43 (-1.51%) ▼|T20.65-1.18 (-5.39%) ▼|TMO503.65-2.77 (-0.55%) ▼|TMUS167.70-6.28 (-3.61%) ▼|TSLA421.79+9.95 (+2.42%) ▲|TXN299.68+14.20 (+4.97%) ▲|UBER72.17-3.34 (-4.42%) ▼|UNH416.17-3.66 (-0.87%) ▼|UNP271.92-0.78 (-0.29%) ▼|UPS107.49-0.52 (-0.48%) ▼|USB60.57-0.20 (-0.32%) ▼|V343.09+1.44 (+0.42%) ▲|VZ42.32-1.79 (-4.05%) ▼|WFC82.79-0.72 (-0.86%) ▼|WMT113.08-1.52 (-1.33%) ▼|XOM136.52+0.46 (+0.33%) ▲|
31.4 C
New York
Tuesday, June 30, 2026

Tag: guidance

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

D-Bal Max 2025: Exploring the Science and Safety behind a Popular And Legal Dianabol Steroid For Muscle Growth

Glasgow, June 15, 2025 (GLOBE NEWSWIRE) --

In the quest for enhanced athletic performance and muscle growth, many fitness enthusiasts and bodybuilders turn to supplements. D-Bal Max has emerged as a noteworthy option that claims to replicate the muscle-building benefits of anabolic steroids, but with a natural and safer approach.

Evaluating the True Value of a Financial Adviser for Strategic Asset Management

**The Systematic Approach to Achieving Financial Independence** Investing in low-cost mutual funds can be an effective strategy for individuals seeking to manage their own financial...

Eve Air Mobility and Revo Accelerate Urban Air Mobility with $250M Contract

A fleet of up to 50 aircraft and aftermarket services is poised to revolutionize urban transport across Revo's key markets. PARIS, June 15, 2025 /PRNewswire/ -- Eve Air Mobility ("Eve") (NYSE: EVEX) (NYSE: EVEXW) has signed its first binding framework agreement with...

Eve Air Mobility Twenty-Year Market Outlook Highlights Growth of Urban Air Mobility Globally

Outlook highlights a $280 billion passenger revenue and 30,000 aircraft opportunities driven by urban population growth, traffic concerns, and a commitment to sustainability. PARIS,...

China, Central Asia make continuous efforts to deepen agricultural cooperation

BEIJING, June 15, 2025 /PRNewswire/ -- A report from People's Daily: ...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

ELV SHAREHOLDERS: Elevance Health, Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 11 Deadline (NYSE:ELV)

Elevance Health, Inc. investors that lost money are notified to contact BFA Law before July 11, 2025 securities fraud class action deadline.

CIVI SHAREHOLDERS: Civitas Resources, Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 1 Deadline (NYSE:CIVI)

Civitas Resources, Inc. investors that lost money are notified to contact BFA Law before July 1, 2025 securities fraud class action deadline.

IOVA SHAREHOLDERS: Iovance Biotherapeutics, Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 14 Deadline (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc. investors that lost money are notified to contact BFA Law before July 14, 2025 securities fraud class action deadline.

TEM Investor Notice: Robbins LLP Reminds Shareholders of the Class Action Lawsuit Against Tempus AI, Inc. Class Action

Robbins LLP is Investigating Allegations that Tempus AI, Inc. (TEM) Misled Investors Regarding its Business Prospects

Life Science Labs Signal Shifting Strategies Amid New Economic Pressures, According to Survey of 550+ Researchers

ARLINGTON, Va., June 13, 2025 /PRNewswire/ -- New survey insights reveal a measurable shift in how life science labs are responding to global financial uncertainty,...

Safe Harbor Financial CEO Terry Mendez to Serve as “Shark” during Conscious Capitalist Sessions at Psychedelic Science 2025

Industry Veteran to Join Global Impact Leaders in Psychedelic Innovation Workshop at World’s Largest Psychedelic Conference
Industry Veteran to Join Global Impact Leaders in Psychedelic Innovation Workshop at World’s Largest Psychedelic Conference

Psychic Hotline | Accurate Psychic Phone Readings by Certified Experts – Special 2025 Announcement

Discover a trusted psychic hotline offering accurate psychic phone readings 24/7 by certified advisors for love, career, and life guidance – Newly launched for 2025 by The Psychic Experts.
Discover a trusted psychic hotline offering accurate psychic phone readings 24/7 by certified advisors for love, career, and life guidance – Newly launched for 2025 by The Psychic Experts.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsGuidance